SMi presents its 20th annual

**European Pricing and Reimbursement**

Evaluate HTA Reforms and Market Access Processes to Optimise Business Profit

Marriott Regents Park Hotel, London

**Benefits of attending:**
- Evaluate challenges within price discrimination
- Implications of AMNOG featuring Iges Institut, EUCope and Ministry of Health, Germany
- Case study from Ipsen on latest developments in pharmaceutical pricing
- Analyse the impact of Value Based Assessment on SMEs
- Gain further insight on how to engage effectively with payers
- Key presentation on the IMI GetReal consortium

**Chairs for 2014:**
- Peter Hertzman, Nordic Market Access Director, BMS
- Leslie Galloway, Chairman, Ethical Medicines Industry Group (EMIG)

**Key Speakers Include:**
- Leyla Hannbeck, Head of Pharmacy Services, National Pharmacy Association
- Silke Baumann, Head of Unit, Pricing, Assessment and Reimbursement of New Medicines, Ministry of Health, Germany
- Rodolphe Perard, Associate Director, Market Access, Gilead
- Francois Bernard, Head of Market Access, Mundipharma
- Mike Chambers, Head of Reimbursement and Value, Market Access and Healthcare Solutions, GlaxoSmithKline
- Linda van Saase, Manager, Pharmaceutical Care, National Healthcare Institute
- Irma van den Arend, VP, Global Pricing, Reimbursement and Funding, Ipsen
- Mete Saylan, Senior Market Access Manager, Novartis

**PLUS TWO INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOPS**

**A: PPRS: A roadmap to understanding the changes and ensuring effective engagement and optimal pricing**

Workshop Leader: Christian Hill, Director, Market Access and Government Affairs, Map Biopharma Ltd

9.00am - 12.30pm

**B: A multi-perspective approach to defining value to achieve optimal market access in Europe**

Workshop Leaders: Eimear Lochlainn, Director, Value Insight & Communication and Jennifer Cook, Director, Value Insight & Communication, Adelphi Values

1.30pm – 5.30pm

www.pharmaceuticalpricing.co.uk

Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711

ACADEMIC & GROUP DISCOUNTS AVAILABLE
European Pricing and Reimbursement
Day One | Monday 13th October 2014

9.30 Registration & Coffee

10.00 Chairman’s Opening Remarks
Peter Hertzman, Nordic Market Access Director, BMS

SPOTLIGHT ON PRICE DISCRIMINATION AND MARKET ACCESS

10.10 Keynote Address
Price discrimination – gaining an overview
• What does price discrimination mean and why is relevant?
• Evaluating challenges and obstacles for price discrimination
• How are differences in HTA approaches between countries influencing price discrimination?
• Various options to achieve price discrimination, including outcome based contracts
Peter Hertzman, Nordic Market Access Director, BMS

10.50 Examining diverse perspectives on market access
• How do different regions approach and manage market access?
• Assessing different treatment pathways geographically and the impact of these on the industry
• Comparing market access strategies varying to class of drugs
Rodolphe Perard, Associate Director, Market Access, Gilead

11.30 Morning Coffee

CASE STUDIES, REFORMS AND HTA ASSESSMENTS

11.50 AMNOG and Early Benefit Assessment – Situation and trends
• 3 years of AMNOG and EBA – lessons learned
• Implications of the first modification law (effective April 1, 2014)
• Moving forward
• Case study of system in action
Professor Dr. Bertram Häussler, CEO, IGES Institut GmbH

12.30 Value Based Assessment
• What difference will it make?
• Issues for the pharmaceutical industry
• Issues for SMEs
Leslie Galloway, Chairman, Ethical Medicines Industry Group (EMIG)

1.10 Networking Lunch

2.10 Engagement with payers – how to successfully engage with payers and be heard
• How payers work with the pharma industry and what are the key faci
• What does a successful payer/pharma relationship look like
• How to approach payers using a patient-centric approach
Leyla Hannbeck, Head of Pharmacy Services, National Pharmacy Association

2.50 Pharmaceutical Pricing & Market Access Opportunities and Limitations in Turkey after Implementation of Health Transformation Reform
• Brief overview of Turkish Health Transformation Reform to understand current Pricing & Market Access environment
• What does HTR include? What are the implications?
• Overview of marketing authorisation, pricing and reimbursement process in Turkey: delays, limitations, potential risks in reference price
• Early access opportunities (Pre-license reimbursement via importation from EU or US)
• Managed Entry Agreements in Turkey: What do current regulations allow you to do? What are the opportunities in the near future with the implementation of new pricing decree and reimbursement guideline?
• Are there price increase opportunities?
• Case studies related to above topics
Mete Saylan, Senior Market Access Manager, Novartis

3.30 From value based pricing to value based buying
• How to support health systems in making the right value based decisions
• Making the transition from product value to value delivered in the real environment
• How can the industry engage with local payers and deliver value
• Supporting value based decisions by demonstrating measurable results of new drugs
Janice Haigh, Practice Leader, Market Access, Quintiles

4.10 Afternoon Tea

4.30 AMNOG - Value Based Pricing in Germany
• What do we know now? Lessons learned
• Explaining the latest legislation
• Evaluating changes in P&R and the German landscape
Silke Baumann, Head of Unit, Pricing, Assessment and Reimbursement of New Medicines, Ministry of Health, Germany

5.10 AMNOG and its international implications
• Choice of comparators
• International reference pricing
• Price transparency
• How are orphan medicines and products handled?
Dr Alexander Natz, Director General, EUCOPE

5.50 Chairman’s Closing Remarks and Close of Day One

6.00 Drinks Reception sponsored by

Sponsored by

Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 29,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com

Want to know how you can get involved?
Interested in promoting your services to this market?
Contact Daniel Lee, SMi Marketing on +44 20 7827 6078, or email: dlee@smi-online.co.uk

Register online at: www.pharmaceuticalpricing.co.uk • Alternatively for

Quintiles
8.30  Registration & Coffee

9.00  Chairman’s Opening Remarks
Leslie Galloway, Chairman, Ethical Medicines Industry Group (EMIG)

9.10  KEYNOTE ADDRESS
EU Pricing & Market Access from a Global Perspective
- Examining the latest developments in pharmaceutical pricing
- Price management in the context of International Price Referencing and Class Referencing
- Discussion of market access strategies and a case study of a system in action
Irma van den Arend, VP Global Pricing, Reimbursement and Funding, Ipsen

9.50  Case study presentation: developing a co-creation model with payers
- Understand payer preferences on patient pathway optimization
- Identify and develop solutions to co-create incremental value with external stakeholders including payers
- Moving our customer market access model from a “push” to a “pull” approach
François Bernard, Head of Market Access, Mundipharma

10.30  Morning Coffee

11.00  DEVELOPMENTS IN MEDICINE DEVELOPMENT
Is there room for real world data in medicine development?
- The emerging environment: conditional and adaptive processes for marketing authorisation and reimbursement
- The use of ‘real world’ data in generating early estimates of relative effectiveness
- The IMI GetReal consortium: towards a shared framework for decision making
Mike Chambers, Head of Reimbursement and Value, Market Access and Healthcare Solutions, GlaxoSmithKline

11.40  Market access for innovative products: what’s new in France?
- Examining Actual Benefit (SMR) and Improvement Actual Benefit (ASMR) since 2005
- New legislation for France since October 2013: What is the impact?
- Demonstrating medical and economic values in real life
Côme de Sauvebeuf, Associate, Price and Market Access Department, Kamedis Conseils

12.20  Networking lunch

1.40  DISCUSSION OF FUTURE IN P&R
JAPAN

1.40  Japanese Pricing and Reimbursement After the 2014 Reforms
- Changes to launch pricing rules
- Role of premium for new drug development
- New measures for off-patent brands and generics
- Whatever happened to demands for cost effectiveness?
Donald Macarthur, Global Pharmaceutical Business Analyst, DM Pharma Issues Ltd

2.20  The future scenario of P&R: health reforms and companies’ strategies
- Demand and offer of pharmaceuticals as public health criticism
- Actions by pharma agencies: NICE and others
- Sustainability of innovation
- Approaching new paradigms for companies
Professor Fabrizio Granfate, Professor of Healthcare and Pharmaceutical Economics, University LUISS, Rome

3.00  Afternoon Tea

3.30  The proposed reform of the EU Transparency Directive – an Update
- Introduction
- Transparency Directive (89/105)
- ECJ case law interpreting the Directive
- Problems with the current framework
- Review timeline
- Objective of the Commission’s Proposal
- Effects of the proposed reform
- Conclusions
Strati Sakellariou, Associate, White & Case LLP

4.10  A Dutch Approach to Reimbursement
- The impact of personalised medicine on Pricing and Reimbursement
- Clarifying the conundrum of reimbursement authorities
- The dutch solution – implementing boundaries for all stakeholders
- Negotiating the best outcome for healthcare – illustrated with examples
Linda van Saase, Manager, Pharmaceutical Care, National Healthcare Institute

4.50  Panel discussion – managing international challenges of HTA
- Clarifying the impact of European developments on industry
- What is the future of HTA?
- Debating the positives and negatives in future HTA approaches
Janice Haigh, Practice Leader, Market Access, Quintiles
Peter Hertzman, Nordic Market Access Director, BMS
François Bernard, Head of Market Access, Mundipharma

5.30  Chairman’s Closing Remarks and Close of Day Two
Overview of workshop:

Introduced in January this year, the new PPRS pricing scheme represents a major change in how the UK pays for branded medicines. The Pharmaceutical Price Regulation Scheme (PPRS) has been around since the 1950s, but this new version has evolved greatly from its previous incarnation that was running from 2009 to 2013. Until January 2014, the PPRS was a ‘profit cap and price cut’ system, which controlled the overall UK drugs bill, and allowed free pricing setting at launch by pharmaceutical companies. The new PPRS has a number of novel components introduced alongside existing provisions from the previous PPRS. This workshop will enable attendees from the biotech and pharmaceutical industry to understand the implications for their portfolio of medicines, how the new changes to the PPRS will impact them and ensure optimal pricing strategy is developed and maintained/monitored.

Why you should attend:

Learn about:
• Planning for PPRS and the leveraging it as part of the wider strategy across European markets
• The link between PPRS and HTA organisations in the UK and managing the interrelationship effectively
• Avoiding nasty surprises
• How to negotiate a price rise

Programme:

8.30  Registration and coffee
9.00  Welcome and introductions
9.10  Icebreaker
9.30  Presentation: Overview of the changes in PPRS
10.00 Case studies: the good, the bad, the ugly
10.40 Coffee break - questions on a postcard collected during coffee break
11.00 Interactive discussion: Answers on a postcard session
11.45 Summary and key messages
12.00 Meeting close

About the workshop host:

Christian Hill is Director of Market Access and Government Affairs at Map BioPharma and Map MedTech. He is a seasoned market access professional with over 15 years of experience in the international life sciences industries. He has a broad range of expertise and experience including pricing, HTA submission strategy leading to positive guidance, health economic modelling development, and relationships with access and reimbursement bodies and their influencers across Europe, with a specific focus on the UK and Ireland.

He is also a member of the board at EUCOPE, a trade body in Europe representing Medtech and BioPharma companies; and a member of the steering group of EMIG, a UK trade body representing primarily SMEs.

About Map BioPharma

Map offers consultancy services that help MedTech and BioPharma clients achieve optimal market access in Europe with a special focus on the UK & Ireland and Germany. This is achieved through a combination of a web based subscription service which aims to act as a ‘virtual’ expert to hold your hand as you navigate the processes; and through one to one strategic advice, support for product profiling, pricing and dossier development and to support lobbying activity for when a plan B is needed.
Overview of workshop:
The workshop will provide an overview of the EU healthcare environment, challenges as well as the processes. Key aspects of the workshop will include:
• An EU perspective of market access, with insights into upcoming changes/developments highlighting differences and similarities between countries and regional differences where applicable
• Identification of key stakeholders and decision makers, how they assess value and what their needs and decision drivers are
• Review of the general clinical and economic evidence requirements and consideration for clinical development programmes to meet regulatory/HTA hurdles

Why you should attend:
This workshop will provide an understanding of the EU healthcare systems, P&R processes, increase your understanding of the challenges and opportunities within the EU market access environment and identify how to define value for different stakeholders and customize value propositions to optimize P&R success.

Programme:
13:00     Registration & coffee
13:15      Examining diverse perspectives on market access
14:00      Why is value important – moving away from price
14:45     Coffee break
15:15     Assessing value for different stakeholders - meet the payer
16:00      Interactive discussion – how do you assess value?
16:40     Reviewing requirements to meet HTA challenges
17:15     Close of workshop
* agenda may be subject to change

About the workshop host:
Eimear Lochlainn, Director, Value Insight and Communication. With over 20 years international experience in the pharmaceutical & biotechnology industry, NHS Scotland, Scottish Medicines Consortium (SMC), academia and consulting, Eimear has managed, led, developed and implemented global market access strategies for new pharmaceuticals, diagnostics and vaccines. She has also been an economic assessor and advisor to the SMC, appraising reimbursement submissions from the pharmaceutical industry seeking a positive formula listing. Eimear has extensive experience managing multidisciplinary collaborative teams with various stakeholders and has technical expertise in information science and synthesising statistical, clinical, economic, public health and commercial evidence to formulate strategic market access plans.

Jennifer Cook, Director, Value Insight and Communication. Jennifer has broad and extensive experience within the pharmaceutical industry; immediately prior to joining Adelphi Values she worked as a Global Pricing and Market Access Director for AstraZeneca, developing payer pricing and market access strategies and shaping evidence needed for payer value stories, to gain reimbursement. Her earlier industry experience includes roles in sales, marketing, and market analysis. As one of the directors at Adelphi Values, Jennifer informs client decisions through the investigation, demonstration and communication of healthcare value, working across a range of therapeutic areas.

About Adelphi Values
Adelphi Values is a global patient-centered research and healthcare value consultancy combining strategic thinking with a reputation for excellence in outcomes research, health economics, and market access. By understanding and addressing the challenges of our clients, we help bring healthcare products and services to the market successfully by investigating, developing and communicating scientific evidence that defines value, informs decisions and benefits patients.
CONFERENCE PRICES

I would like to attend: (Please tick as appropriate) Fee Total
☐ Conference & 2 Workshops £2697.00 + VAT £3236.40
☐ Conference & 1 Workshop £2098.00 + VAT £2517.60
☐ Conference only £1499.00 + VAT £1798.80
☐ 1 Workshop only £599.00 + VAT £718.80
☐ 2 Workshops only £1198.00 + VAT £1437.60
Workshop A ☐ Workshop B ☐

GROUP DISCOUNTS AVAILABLE

PROMOTIONAL LITERATURE DISTRIBUTION
☐ Distribution of your company’s promotional literature to all conference attendees £999.00 + VAT £1198.80

Unable to travel, but would like to watch the conference live, ask questions, participate as if you were in the room?
☐ Live Streaming £999.00 + VAT £1198.80
☐ On demand (available 24 hours after the event) £599.00 + VAT £718.80
☐ Access to the conference documentation on the Document Portal £499.00 + VAT £598.80
☐ The Conference Presentations – paper copy (or only £300 if ordered with the Document Portal) £499.00

PAYMENT

Payment must be made to SMI Group Ltd, and received before the event, by one of the following methods quoting reference P-120 and the delegate’s name. Bookings made within 7 days of the event require payment on booking, methods of payment are as follows. Please indicate method of payment:

☐ UK BACS
☐ Wire Transfer
☐ Cheque
☐ Credit Card
☐ American Express
☐ Visa
☐ MasterCard
☐ Bancontact
☐ SEPA
☐ Bancontact
☐ Direct Debit
☐ Other

All credit card payments will be subject to standard credit card charges.

PAYMENTS: £1499.00 + VAT £1798.80

Terms and Conditions of Booking

Payment: If payment is not made at the time of booking, then an invoice will be issued and must be paid immediately and prior to the start of the event. If payment has not been received then credit card details will be requested and payment taken before entry to the event. Bookings within 7 days of event require payment on booking. Access to the Document Portal will not be given until payment has been received.

Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. Two or more delegates may not share a place at an event. Please make separate bookings for each delegate.

Cancellation: If you wish to cancel your attendance at an event and you are unable to send a substitute, then we will refund credit 50% of the due fee less a £50 administration charge, providing that cancellation is made in writing and received at least 28 days prior to the start of the event. Regrettably cancellation after this time cannot be accepted. We will however provide the conference documentation via the Document Portal to any delegate who has paid but is unable to attend for any reason. Due to the interactive nature of the Briefings we are normally able to provide documentation in these circumstances. We cannot accept cancellations of orders placed for documentation or the Document Portal as these are reproduced specifically to order. If we have to cancel the event for any reason, then we will make a full refund immediately, but do not accept further liability.

Attention: It may become necessary for us to make alterations to the content, speakers, timings, venue or date of the event compared to the advertised programme.

Data Protection: The SMI Group gathers personal data in accordance with the UK Data Protection Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other products and services. Unless you tell us otherwise, we may also share your data with third parties offering complementary products or services. If you have any queries or want to update any of the data that we hold then please contact our Database Manager datacessmanagement@smi-online.co.uk or visit our website www.smi-online.co.uk, updates quoting the URN as detailed above your address on the attached letter.

If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at events@smi-online.co.uk